Hoffmann-La Roche initiates study on RO7663498 for diabetic retinopathy
A new study is underway to evaluate the safety, tolerability, and pharmacokinetics of RO7663498 in diabetic retinopathy patients.
Asset / Drug
Drug and asset intelligence for Hoffmann-La with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.